311 related articles for article (PubMed ID: 16707479)
1. DNA methylation changes after 5-aza-2'-deoxycytidine therapy in patients with leukemia.
Yang AS; Doshi KD; Choi SW; Mason JB; Mannari RK; Gharybian V; Luna R; Rashid A; Shen L; Estecio MR; Kantarjian HM; Garcia-Manero G; Issa JP
Cancer Res; 2006 May; 66(10):5495-503. PubMed ID: 16707479
[TBL] [Abstract][Full Text] [Related]
2. Decitabine induces very early in vivo DNA methylation changes in blasts from patients with acute myeloid leukemia.
Claus R; Pfeifer D; Almstedt M; Zucknick M; Hackanson B; Plass C; Lübbert M
Leuk Res; 2013 Feb; 37(2):190-6. PubMed ID: 23158571
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate.
Issa JP; Gharibyan V; Cortes J; Jelinek J; Morris G; Verstovsek S; Talpaz M; Garcia-Manero G; Kantarjian HM
J Clin Oncol; 2005 Jun; 23(17):3948-56. PubMed ID: 15883410
[TBL] [Abstract][Full Text] [Related]
4. Decitabine has a biphasic effect on natural killer cell viability, phenotype, and function under proliferative conditions.
Kopp LM; Ray A; Denman CJ; Senyukov VS; Somanchi SS; Zhu S; Lee DA
Mol Immunol; 2013 Jul; 54(3-4):296-301. PubMed ID: 23328088
[TBL] [Abstract][Full Text] [Related]
5. Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia.
Kantarjian HM; O'Brien S; Cortes J; Giles FJ; Faderl S; Issa JP; Garcia-Manero G; Rios MB; Shan J; Andreeff M; Keating M; Talpaz M
Cancer; 2003 Aug; 98(3):522-8. PubMed ID: 12879469
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of a 7-day continuous intravenous infusion of decitabine: inhibition of promoter-specific and global genomic DNA methylation.
Samlowski WE; Leachman SA; Wade M; Cassidy P; Porter-Gill P; Busby L; Wheeler R; Boucher K; Fitzpatrick F; Jones DA; Karpf AR
J Clin Oncol; 2005 Jun; 23(17):3897-905. PubMed ID: 15753459
[TBL] [Abstract][Full Text] [Related]
7. Effect of cytarabine and decitabine in combination in human leukemic cell lines.
Qin T; Youssef EM; Jelinek J; Chen R; Yang AS; Garcia-Manero G; Issa JP
Clin Cancer Res; 2007 Jul; 13(14):4225-32. PubMed ID: 17634552
[TBL] [Abstract][Full Text] [Related]
8. Decitabine studies in chronic and acute myelogenous leukemia.
Kantarjian HM; O'Brien SM; Estey E; Giralt S; Beran M; Rios MB; Keating M; de Vos D; Talpaz M
Leukemia; 1997 Mar; 11 Suppl 1():S35-6. PubMed ID: 9130691
[No Abstract] [Full Text] [Related]
9. Analysis of genome-wide methylation and gene expression induced by 5-aza-2'-deoxycytidine identifies BCL2L10 as a frequent methylation target in acute myeloid leukemia.
Fabiani E; Leone G; Giachelia M; D'alo' F; Greco M; Criscuolo M; Guidi F; Rutella S; Hohaus S; Voso MT
Leuk Lymphoma; 2010 Dec; 51(12):2275-84. PubMed ID: 21077739
[TBL] [Abstract][Full Text] [Related]
10. Clinical outcome of treatment with a combined regimen of decitabine and aclacinomycin/cytarabine for patients with refractory acute myeloid leukemia.
Song LX; Xu L; Li X; Chang CK; Zhang Y; Wu LY; He Q; Zhang QX; Li X
Ann Hematol; 2012 Dec; 91(12):1879-86. PubMed ID: 22895556
[TBL] [Abstract][Full Text] [Related]
11. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies.
Issa JP; Garcia-Manero G; Giles FJ; Mannari R; Thomas D; Faderl S; Bayar E; Lyons J; Rosenfeld CS; Cortes J; Kantarjian HM
Blood; 2004 Mar; 103(5):1635-40. PubMed ID: 14604977
[TBL] [Abstract][Full Text] [Related]
12. Prognostic impact of the number of methylated genes in myelodysplastic syndromes and acute myeloid leukemias treated with azacytidine.
Abáigar M; Ramos F; Benito R; Díez-Campelo M; Sánchez-del-Real J; Hermosín L; Rodríguez JN; Aguilar C; Recio I; Alonso JM; de las Heras N; Megido M; Fuertes M; del Cañizo MC; Hernández-Rivas JM
Ann Hematol; 2013 Nov; 92(11):1543-52. PubMed ID: 23740492
[TBL] [Abstract][Full Text] [Related]
13. Activation of the p53 DNA damage response pathway after inhibition of DNA methyltransferase by 5-aza-2'-deoxycytidine.
Karpf AR; Moore BC; Ririe TO; Jones DA
Mol Pharmacol; 2001 Apr; 59(4):751-7. PubMed ID: 11259619
[TBL] [Abstract][Full Text] [Related]
14. A single nucleotide polymorphism chip-based method for combined genetic and epigenetic profiling: validation in decitabine therapy and tumor/normal comparisons.
Yuan E; Haghighi F; White S; Costa R; McMinn J; Chun K; Minden M; Tycko B
Cancer Res; 2006 Apr; 66(7):3443-51. PubMed ID: 16585166
[TBL] [Abstract][Full Text] [Related]
15. Changes in DNA methylation patterns in subjects exposed to low-dose benzene.
Bollati V; Baccarelli A; Hou L; Bonzini M; Fustinoni S; Cavallo D; Byun HM; Jiang J; Marinelli B; Pesatori AC; Bertazzi PA; Yang AS
Cancer Res; 2007 Feb; 67(3):876-80. PubMed ID: 17283117
[TBL] [Abstract][Full Text] [Related]
16. Digging deep into "dirty" drugs - modulation of the methylation machinery.
Pleyer L; Greil R
Drug Metab Rev; 2015 May; 47(2):252-79. PubMed ID: 25566693
[TBL] [Abstract][Full Text] [Related]
17. Complete cytogenetic remission after decitabine treatment in a patient with secondary AML harbouring high p15INK4b gene methylation and high global DNA methylation.
Lehmann U; Dobbelstein C; Fenner M; Römermann D; Hasemeier B; Metzig K; Steinemann D; Büsche G; Krauter J; Ganser A; Kreipe H
Ann Hematol; 2009 Mar; 88(3):275-7. PubMed ID: 18704418
[No Abstract] [Full Text] [Related]
18. In vivo effects of decitabine in myelodysplasia and acute myeloid leukemia: review of cytogenetic and molecular studies.
Hackanson B; Robbel C; Wijermans P; Lübbert M
Ann Hematol; 2005 Dec; 84 Suppl 1():32-8. PubMed ID: 16292549
[TBL] [Abstract][Full Text] [Related]
19. The DNA demethylating agent 5-aza-2'-deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cells.
Almstedt M; Blagitko-Dorfs N; Duque-Afonso J; Karbach J; Pfeifer D; Jäger E; Lübbert M
Leuk Res; 2010 Jul; 34(7):899-905. PubMed ID: 20381863
[TBL] [Abstract][Full Text] [Related]
20. Differential TERT promoter methylation and response to 5-aza-2'-deoxycytidine in acute myeloid leukemia cell lines: TERT expression, telomerase activity, telomere length, and cell death.
Pettigrew KA; Armstrong RN; Colyer HA; Zhang SD; Rea IM; Jones RE; Baird DM; Mills KI
Genes Chromosomes Cancer; 2012 Aug; 51(8):768-80. PubMed ID: 22517724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
